Navigation Links
Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
Date:9/11/2007

Results presented at the 6th Annual Meeting of the Society for the

Advancement of Blood Management (SABM). Separate study presented at SABM finds EVICEL* Fibrin Sealant (Human) more effective than manual compression in achieving hemostasis in vascular

surgery.

SOMERVILLE, N.J., Sept. 11 /PRNewswire/ -- A randomized study comparing treatment with plasma-derived human thrombin and thrombin derived from bovine sources shows that human thrombin is as effective as bovine thrombin in achieving hemostasis in patients at three-, six- and 10-minute intervals. The study of 305 patients with mild or moderate bleeding during elective cardiovascular, neurological or general surgical procedures also showed that human thrombin was less likely to result in an immune response in patients as compared to bovine thrombin. Study results were presented Friday at the Society for the Advancement of Blood Management meeting in Los Angeles. The study was supported by ETHICON, Inc.

In the study, the proportion of patients achieving hemostasis at 10 minutes (primary outcome) was 97.4% following treatment with human thrombin and also following treatment with bovine-derived thrombin. The percentages of patients achieving hemostasis at six minutes and three minutes were also equivalent. There were no statistically significant differences in several other variables including laboratory assessments, vital signs, blood loss, blood transfusions, time in specialty-care unit, procedure duration, and length of hospital stay.

On August 27, the U.S. FDA approved EVITHROM* Thrombin, Topical (Human) for use in cardiovascular, neurological and general surgery. EVITHROM* was developed in collaboration with OMRIX Biopharmaceuticals, Inc. ETHICON plans to make the product commercially available in the United States in Q4 2007.

"With EVITHROM*, the first plasma-derived human thrombin, surgeons have a new option for hemos
'/>"/>

SOURCE ETHICON, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009).../PRNewswire/--AccordingtoMillenniumResearchGroup(M...elligence,thenearly$3billionUSmarketfortraumafixat...iveyearsdespitetherecenteconomicslowdown.MRG,s USM...rketwillremainhighlydynamicoverthenextfiveyears,wi...uslyunderservedsegmentsofthetraumafixationmarket,f...
(Date:11/25/2009)...swire/--Reportlinker.comannouncesthatanewmarketres...nasalDrugDelivery-USMarketTrends&Analysis htt...Delivery---US-Market-Trends--Analysis.html ,, ...ansionoftherapeuticapplicationsfromthedeliveryofco...emictherapeuticdrugs.Thefutureofthetechnologyhinge...
(Date:11/24/2009)...PRNewswire-Asia/--ChindexInternational,Inc.,("Chin...oviderofWestern,healthcareproductsandservicesinthe...anywillattendthe21stAnnualPiperJaffray,"Unplugged"...e,NewYorkPalaceHotel. , Managementiscurrently...2009,andholdone-on-onemeetingsthroughouttheday.Awe...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Chindex International to Present at Piper Jaffray Health Care Conference 2Innovative Psoriasis Treatment PSORENT 28R 29 Announces Healthcare Cost Savings Potential Consistent with President Obamas Announcement on Healthcare 4651 1Innovative Psoriasis Treatment PSORENT 28R 29 Announces Healthcare Cost Savings Potential Consistent with President Obamas Announcement on Healthcare 4651 2YWCAs to Mark National HIV Testing Day on June 27 50064 1YWCAs to Mark National HIV Testing Day on June 27 50064 2Bills Address Long Waits for Behavioral Health Patients 50063 1Bills Address Long Waits for Behavioral Health Patients 50063 2Bills Address Long Waits for Behavioral Health Patients 50063 3
...hilcott Limited (Nasdaq: WCRX ) announced today ...rnational Pty. Ltd. ("Mayne"), a subsidiary of Hos...tual Pharmaceutical Company, Inc. ("Mutual"), Myla...ories, Inc. ("Impax") in the District Court for t...e,s U.S. Patent No. 6,958,161 (the ",161 Patent") ...
...me that normal stem cells can act as the source of...Tenn., Dec. 17 /PRNewswire-USNewswire/ -- Scient... answered a central question in cancer biology: wh...tem cells are immature cells that can renew themse...that compose the range of body tissues. In recent ...
Other Medicine Technology:Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3Molecular Marker Identifies Normal Stem Cells as Intestinal Tumor Source 2Molecular Marker Identifies Normal Stem Cells as Intestinal Tumor Source 3
(Date:11/25/2009)...thertoShareRecordsSafely,ImproveCare ,, WASHI...ofVeteransAffairs(VA)andKaiserPermanentetodayannou...cestoourNation,sheroes.VAandKaiserPermanentearelau...d(EHR)informationusingtheNationwideHealthInformati...manServices. ,, "Theabilitytosharecriticalhealt...
(Date:11/25/2009)...Nov.25/PRNewswire/--dazzlesmile,llc www.dazzlesmil...hscience.com havefileda67-pagefederallawsuitagains...esseWillms,FarendServicesLimited,andAtLastFulfillm...istrictCourtfortheDistrictofUtah,allegesmassivenat...brandedteethwhiteningproducts,violationsoftheRacke...
(Date:11/25/2009)...,Nov.25/PRNewswire/--DanielTouizer,CEOof Ci n e...uehealthinsurancebenefitprograms,isconcernedthatth...arlyoneinfiveAmericansarewithoutafull-timejobandun...ntratesaredeterminedbytheU-6number,whichhasspikedt... l T ouizer ."Thesestatisticsarealarmingasitmea...
(Date:11/25/2009)...naling pathways essential to normal human developm...factor receptor (EGFR) pathways - interact in ways...is, researchers from The University of Texas M. D....e of Molecular Cell . , This newly characterize...known to correlate with invasive cancer - activati...
(Date:11/25/2009)...American Society of,Hematology (ASH) is pleased t...,the highest scoring abstracts in the categories ...te student, resident physician, and post-doctoral,...rium plus annual meeting,travel reimbursement. ,...raduate,Student , Kimberly Fan , Donor Dendri...
Breaking Medicine News(10 mins):Health News:VA and Kaiser Permanente Invite Veterans to Participate in Health Record Pilot Program 2Health News:dazzlesmile Sues Epic Advertising and Jesse Willms 2Health News:Cinergy Health Commentary on Health Care for the Unemployed 2Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 2Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 3Health News:ASH announces 2009 Merit Award winners 2
...a., Feb. 18 The Quantum Group,Inc. (NYSE Amex: ...el J. Guillama,commented on the President signing ... into law yesterday. The new law allocates $19.2 ..., The new law provides for approximately $17 b...
...., Feb. 18 In a dramatic move to unite the,power ...organizations, the,United American Nurses, Califor...Committee, and the Massachusetts Nurses Associatio...urses-National,Nurses Organizing Committee, UAN-NN...
... Express flights not always owned and operat...f care , Cleveland, Ohio ...lane crash of Continental Flight 3407 near Buffa...expert and lawyer Jamie R. Lebovitz points out tha...
... JIVA™ Resveratrol Synergistic Supplem... Mount Kisco, NY (PRWEB) Febr...ated as much excitement as resveratrol . It,s bee...ute on Aging created a stir when they published a ...
... Conference Call for Wednesday, February 18, 2009 ...difast, Inc. (NYSE: MED ), a leading clinically-...unced today that it will hold an investor call at ...y Minkow and the Fraud Discovery Institute. , , "...
...livers Critical Support to Hispanic Family Budgets...dent and CEO of the National Alliance for Hispanic...cacy group, delivered the following statement on t...panic families are an illness or hospital stay awa...
Other Medicine News:Health News:The Quantum Group Compliments Congress and President Obama on Signing of Stimulus Bill into Law 2Health News:The Quantum Group Compliments Congress and President Obama on Signing of Stimulus Bill into Law 3Health News:The Quantum Group Compliments Congress and President Obama on Signing of Stimulus Bill into Law 4Health News:Aviation Expert Addresses Flight Safety Concerns 2Health News:Aviation Expert Addresses Flight Safety Concerns 3Health News:Aviation Expert Addresses Flight Safety Concerns 4Health News:Physician Develops Resveratrol Evidence-Based Nutraceutical for Heart Health 2Health News:Physician Develops Resveratrol Evidence-Based Nutraceutical for Heart Health 3Health News:Medifast, Inc. Responds to False Claims 2Health News:Medifast, Inc. Responds to False Claims 3Health News:Medifast, Inc. Responds to False Claims 4Health News:Statement of the National Alliance for Hispanic Health on Signing of the American Recovery and Reinvestment Act 2
SEDIPLAST ESR SYSTEM (with diluent)
SEDIPLAST ESR SYSTEM (without diluent)
Hemaprompt FG Gastric and Fecal Occult Blood Test
... occult blood test (FOBT) has been aiding physicia... an early indication of colorectal cancer. More th...hich were conducted over long periods of time with...d in leading medical journals around the world. As...
Medicine Products: